NCT06739317 - SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. | Biotech Hunter

Enrollment

398

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

June 30, 2031

Conditions

Unresectable Hepatocellular Carcinoma (HCC)

Interventions

RADIATION

Radiation

Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.

DRUG

First line therapy

Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.

DRUG

First line therapy

Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.

PROCEDURE

operation

If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.

Trial Locations (1)

the First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER